Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple‐Negative Breast Cancer

Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple‐Negative Breast Cancer

Abstract Dysregulated eEF2K expression is implicated in the pathogenesis of many human cancers, including triple‐negative breast cancer (TNBC), making it a plausible therapeutic target. However, specific eEF2K inhibitors with potent anti‐cancer activity have not been available so far. Targeted prote...

Full description

Bibliographic Details
Main Authors: Changxin Zhong, Rongfeng Zhu, Ting Jiang, Sheng Tian, Xiaobao Zhao, Xiaoya Wan, Shilong Jiang, Zonglin Chen, Rong Gong, Linhao He, Jin‐Ming Yang, Na Ye, Yan Cheng
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Advanced Science
Subjects:
degrader
eEF2K
molecular glue
triple‐negative breast cancer
Online Access:https://doi.org/10.1002/advs.202305035

Internet

https://doi.org/10.1002/advs.202305035

Similar Items